STAAR Surgical appoints Deborah Andrews as CFO

LAKE FOREST, Calif. - STAAR Surgical Company (NASDAQ:STAA), currently trading at $17.04 with a market capitalization of $851 million, has appointed Deborah Andrews as Chief Financial Officer, effective June 25, 2025, according to a company press release. Andrews, who has been serving as Interim CFO since March 2025, previously held the CFO position at STAAR from 2007-2013 and 2017-2020.

CEO Stephen Farrell stated that Andrews has already "driven greater financial and operating rigor across the organization," putting the company on track to achieve its targeted $225 million annual SG&A run rate ahead of schedule.

The company also announced the formation of a new Capital Stewardship Committee of its Board of Directors, to be chaired by board member Lilian Y. Zhou. The committee will focus on guiding the company’s financial strategies, including capital allocation and management.

As part of broader cost reduction efforts, STAAR has restructured its investor relations function, resulting in the departure of Brian Moore, Vice President of Investor Relations and Corporate Development, effective June 27, 2025.

STAAR Surgical specializes in implantable phakic intraocular lenses for vision correction, particularly its EVO family of Implantable Collamer Lenses. The company reports having sold more than 3 million ICLs in over 75 countries and maintains operations in California and Switzerland.

The announcements come as part of the company’s efforts to improve its cost structure while pursuing growth opportunities with its proprietary Collamer material.

In other recent news, STAAR Surgical announced first-quarter revenues of $43 million, surpassing both the consensus estimate and their own guidance of $40 million. Jefferies responded by raising its price target for the company from $18.00 to $21.00, while maintaining a Hold rating. Additionally, Stifel analysts reaffirmed a Buy rating with a $20.00 price target, citing a 9% year-over-year growth outside of China. Meanwhile, Canaccord Genuity increased its price target from $17.00 to $20.00, maintaining a Hold rating despite challenges in the first quarter. STAAR Surgical’s Board of Directors authorized a $30 million stock buyback, reflecting confidence in the company’s growth prospects. The buyback will be funded by the company’s cash reserves, which stood at $222.8 million as of March 28, 2025. Piper Sandler maintained a Neutral rating with a $16.00 price target, pointing to ongoing challenges in China and recent management changes. Despite these hurdles, STAAR Surgical plans to launch its Evo+ (V5) lens in China this summer, aiming to address the competitive landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.